BD Diagnostics welcomes regulatory approval for BD MAX system
BD Diagnostics has received CR Mark approval for its BD MAX MRSA assay.
The device can rapidly detect the superbug in samples, aiding infection control measures in hospitals.
“When we launched BD MAX earlier this year, our goal was to provide a next-generation molecular testing system designed to accommodate a broad range of assays that laboratories want and need,” said company president, Tom Polen.
“As the first healthcare-associated infection assay developed by BD for use on the BD MAX System, this milestone represents further confirmation of the potential of this fully-automated system. This enables laboratories to offer a broad range of molecular tests that meet both their current and future clinical needs.”